Syndax Pharmaceuticals
SNDX
69 hedge funds and large institutions have $89.1M invested in Syndax Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 14 closing their positions.
600% more call options, than puts
Call options by funds: $350K | Put options by funds: $50K
29% more capital invested
Capital invested by funds: $68.9M → $89.1M (+$20.2M)
5.59% more ownership
Funds ownership: 62.28% → 67.88% (+5.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
7% less funds holding
Funds holding: 74 → 69 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.84M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.46M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$569K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$557K |
| 5 |
Renaissance Technologies
New York
|
+$488K |
Top Sellers
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$780K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$673K |
| 3 |
Morgan Stanley
New York
|
-$476K |
| 4 |
BlackRock
New York
|
-$441K |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$377K |
SNDX Hedge Fund Activity: Q1 2019 in Review
69 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2019, worth a combined $89.1M — up 29% from $68.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SNDX and 9 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 21 added.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $8.84M. The largest seller was Sofinnova Investments, cutting an estimated $780K.
- 69 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2019, down from 74 in Q4 2018.
- Funds reported $89.1M of Syndax Pharmaceuticals stock for Q1 2019, up 29% quarter-over-quarter.
- 9 funds opened new Syndax Pharmaceuticals positions in Q1 2019 and 14 closed out, a net change of -5 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2019 was Adage Capital Partners, an estimated $8.84M added.
- The largest Syndax Pharmaceuticals seller in Q1 2019 was Sofinnova Investments, an estimated $780K sold.
Based on aggregated 13F filings for Q1 2019.